Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health: A Transdiagnostic, Personalized Neuromodulation and Neuroimmune Study to Develop Objective Endpoints and Risk/Durability Profiles for Rapid-Acting Interventions (RESYNC-BH)

NCT07812987 is registered in ClinicalTrials.gov with Tactical Mind Research Coalition, Inc. as lead sponsor.

NCT NCT07812987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health: A Transdiagnostic, Personalized Neuromodulation and Neuroimmune Study to Develop Objective Endpoints and Risk/Durability Profiles for Rapid-Acting Interventions (RESYNC-BH)
Lead sponsor
Tactical Mind Research Coalition, Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 1, 2026
Completion date
December 31, 2028
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, anxiety, depression disorders, executive function, post-traumatic stress, ptsd, sleep disturbance, substance use